Latest Regulatory Progress News

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

Lithium Plus Minerals has secured a 20-year mining lease for its Lei Lithium Project and progressed key environmental and mining studies, while also preparing exploration programs for its gold and critical minerals projects.

BlinkLab Limited has delivered strong diagnostic results in its U.S. autism pilot study, exceeding FDA performance thresholds and setting the stage for a pivotal 510(k) trial. The company also expanded its clinical trial network and nears completion of its European ADHD study.

Mach7 Technologies reports a positive operating cash flow in Q2 FY26, securing its first customer for the new Flamingo Architecture product and advancing key strategic initiatives.

Lake Resources NL reported a solid quarter ending December 2025, progressing regulatory approvals for its Kachi Lithium Brine Project while slashing cash outgoings by 45% year-on-year and maintaining strong liquidity amid a sharp lithium price rally.

Medical Developments International has posted positive operating cashflow for the first half of FY26, driven by robust growth in its flagship product Penthrox across Australia and Europe, alongside progress in paediatric approvals.

Brockman Mining Limited reports significant progress on its Pilbara iron ore projects, advancing joint ventures and infrastructure plans while delivering promising exploration results at Punda Springs.

Truscott Mining Corporation has initiated a fully subscribed capital raising to fund a 2500-metre drilling program at its Westminster Gold Project, targeting core ore bodies with potential multi-million ounce gold mineralisation.

Lumos Diagnostics reported a strong surge in FebriDx® sales alongside positive FDA feedback, securing full Medicare reimbursement and advancing key clinical studies.

Syntara Limited has made significant strides in its clinical pipeline, launching new trials and receiving key regulatory designations, positioning 2026 as a pivotal year for the company.

Saferoads Holdings Limited reported a modest rise in quarterly sales and a half-year net profit of approximately $511k, while progressing regulatory approval for its innovative HV2 barrier.